About this episode
Eric relays his dispatch from Dimension Capital’s biotech summit in Park City, where the crowd was much more academic than the conferences we usually attend. Biotech stocks aren’t doing great, meanwhile university funding cuts could spell trouble for drug research. Still, people were rosy about AI tools.
We also took a temperature check on the state of fintech, which investors tell us is mixed. Everyone’s hopeful about IPOs and streamlined stablecoins, but the dollar getting destabilized by the tariffs has some investors skittish. Later in the episode, Madeline explains how Trump’s crackdown on immigration is spooking startup founders and employees.
Timestamps: 00:42 Lineup of our upcoming fintech summit02:02 Eric's dispatch from Dimension Capital and Recursion's biotech summit09:22 Fintech IPOs and stablecoins en vogue18:50 Heightened immigration enforcement spooks startup employees
Get every episode summarized
Each time The Newcomer Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Newcomer Podcast
Sam Parr on The Hustle, Hampton & Why the OpenAI-TBPN Deal Was a Mistake
The Newcomer Podcast
This AI Was Trained on a Billion Video Game Clips. Now It Controls Robots.
The Newcomer Podcast
John Coogan on Selling TBPN to OpenAI, Sam Altman & the Future of Tech Media
The Newcomer Podcast
Taylor Lorenz Unfiltered on Social Media, Free Speech & the Surveillance State
The Newcomer Podcast